Inebilizumab (Uplizna) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics · 06.07.2026 · 68 (1758) · 110-111
DOI: 10.58347/tml.2026.1758d ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.07.2026.
Abstract (Originalsprache)
The FDA has approved the CD19-directed cytolytic antibody inebilizumab (Uplizna – Amgen) for IV treatment of generalized myasthenia gravis (gMG) in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The neonatal Fc receptor (FcRn) blockers rozanolixizumab (Rystiggo), nipocalimab (Imaavy), and efgartigimod alfa (Vyvgart; Vyvgart Hytrulo) are also approved for such use (see Table 1).
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Inebilizumab (Uplizna) for Myasthenia Gravis. The Medical Letter on Drugs and Therapeutics, 68(1758), 110-111. https://doi.org/10.58347/tml.2026.1758d
Vancouver
Inebilizumab (Uplizna) for Myasthenia Gravis. The Medical Letter on Drugs and Therapeutics. 2026;68(1758):110-111. doi:10.58347/tml.2026.1758d
BibTeX
@article{euvimed2026,
title = {Inebilizumab (Uplizna) for Myasthenia Gravis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1758},
pages = {110--111},
doi = {10.58347/tml.2026.1758d}
}
EUVIMED